Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) Return on Sales: 2016-2023

Historic Return on Sales for Spyre Therapeutics (SYRE) over the last 4 years, with Jun 2023 value amounting to -221.95%.

  • Spyre Therapeutics' Return on Sales fell 21699.00% to -221.95% in Q2 2023 from the same period last year, while for Jun 2023 it was -221.95%, marking a year-over-year decrease of 21699.00%. This contributed to the annual value of -382.38% for FY2023, which is 34639.00% down from last year.
  • Per Spyre Therapeutics' latest filing, its Return on Sales stood at -221.95% for Q2 2023, which was down 232.36% from -66.78% recorded in Q1 2023.
  • Spyre Therapeutics' Return on Sales' 5-year high stood at -2.57% during Q4 2021, with a 5-year trough of -221.95% in Q2 2023.
  • Moreover, its 3-year median value for Return on Sales was -4.96% (2022), whereas its average is -39.68%.
  • Data for Spyre Therapeutics' Return on Sales shows a maximum YoY slumped of 21,699bps (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' Return on Sales (Quarterly) stood at -2.57% in 2021, then crashed by 3,342bps to -35.99% in 2022, then crashed by 21,699bps to -221.95% in 2023.
  • Its Return on Sales was -221.95% in Q2 2023, compared to -66.78% in Q1 2023 and -35.99% in Q4 2022.